The Senate Health, Education, Labor and Pensions Committee was scheduled to vote on Dr. Heidi Overton's nomination on Wednesday. On Tuesday evening, the White House withdrew it. The committee never took the vote, and the Food and Drug Administration, an agency with a full plate of vaccine, tobacco, drug and food decisions, still has no confirmed commissioner.

The withdrawal is a personnel story with a structural consequence. The FDA has been run by an acting commissioner since the last confirmed leader left, and the acting arrangement is now likely to last into the next Congress. Overton's nomination was supposed to end that arrangement. Instead it became the third high-profile health nomination the White House has pulled.

The vote that never happened

Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated in August to replace Marty Makary. The HELP Committee has eleven Democrats and twelve Republicans. With every Democrat opposed, she needed all twelve Republican votes to advance.

By Tuesday, that support was not there. A senior administration official told Axios that she "lacks the support on the Hill," according to the New York Post, and the White House confirmed the withdrawal to the paper. The vote had been scheduled for Wednesday, one day after the nomination came out.

The timing matters. A withdrawal the day before a committee vote is a recognition that the votes were not there, not a decision made after a public defeat. It also means the committee never had to record where each senator stood.

What the committee was weighing

Overton's record touched three of the most contested areas in health policy at once.

On vaccines, Republicans on the committee questioned whether she would be independent of President Trump, who has repeatedly challenged the measles vaccine and the childhood schedule. On tobacco, she faced criticism over past work tied to vaping and flavored e-cigarettes, with senators questioning her ties to the industry. On abortion, Democrats and abortion-rights groups opposed her because of her anti-abortion record, including advocacy for restricting mifepristone.

None of those positions was a surprise. Her confirmation hearing in September covered them, and the hearing produced a memorable exchange in which she affirmed vaccine safety but declined to contradict the president on the measles shot. The record was clear enough for both coalitions to organize against her.

The two coalitions that ended the nomination

The unusual feature of this nomination is that it was opposed from two directions at once.

Republican senators including Bill Cassidy, Susan Collins and Lisa Murkowski raised concerns about her independence on vaccines and her approach to flavored e-cigarettes. The criticism from the right was not uniformly about policy. It also carried a personnel argument: that Overton was not the candidate to carry out the health agenda that Robert F. Kennedy Jr., the health secretary, has described.

Kennedy's allies made that case publicly. Figures aligned with the MAHA movement, including Calley Means, Vani Hari and Alex Clark, celebrated the withdrawal and accused Overton of sidelining Kennedy's priorities. Her relationship with Kennedy was described as icy.

Democratic opposition ran on a different track. Abortion-rights groups and Senate Democrats focused on her anti-abortion record and her support for restricting mifepristone. For them, the nomination was a test of whether the administration would put an abortion opponent in charge of the agency that regulates the drug.

The two coalitions did not agree on much. They agreed that Overton should not lead the FDA. That is enough to stop a nomination that needed every Republican vote.

Cassidy's account, and the White House's

The HELP Committee chairman disputed the arithmetic on Tuesday. Cassidy said the White House "abandoned a viable confirmation path" and that Overton would have had the votes to clear the committee and the full Senate, according to the New York Post.

His account adds a specific reason for the collapse. Cassidy said anti-abortion senators had sought final assurances on "life issues" and that the administration withdrew the nomination rather than commit to them. That is a different explanation from a simple lack of votes. It describes a White House that did not want to pay the price of the assurances.

Both accounts can be true in part. A nomination can be short of the votes on the day and still be winnable with a commitment the White House declined to make. The difference matters because it tells the next nominee what the administration is willing to promise.

An agency led by an acting commissioner

The FDA is now led by acting commissioner Kyle Diamantas. Acting leadership is not unusual in the short term. It becomes a different problem when the decisions in front of the agency are contested and the person making them has not been confirmed by the Senate.

Cassidy said a permanent commissioner will likely be confirmed by Senate Democrats in January, when the new Congress is seated. That is a remarkable admission from the committee's chair. It means the confirmation fight may not be settled by the current Senate at all.

The FDA's authority does not disappear in the meantime. Acting commissioners can sign rules, approve drugs, issue guidance and set enforcement priorities. What changes is the political accountability. A confirmed commissioner answers to the Senate that confirmed them. An acting commissioner answers to the White House that appointed them and, in practice, to the calendar.

The agenda that does not wait

The agency's in-tray is unusually full for a leadership vacuum.

Vaccine policy is the most visible item. The administration has been debating the childhood schedule and the measles vaccine, and the FDA's role in those decisions runs through its biologics and vaccine review functions. A commissioner without Senate confirmation has less standing to push back on the White House, and less reason to.

Tobacco is the second. Flavored e-cigarettes and nicotine pouch regulation are live questions, and the agency has been slow to finish the premarket review process. The industry has learned that delay is a business model.

Drug policy is the third. Mifepristone remains in litigation and under administrative review, and the FDA's decisions on its labeling and distribution have national consequences. Abortion policy is not a side issue for this agency. It is one of the things the commissioner is being confirmed to oversee.

Food and nutrition policy is the fourth. The MAHA movement has made food additives, dyes and ultraprocessed products a priority, and the FDA's food center has been without a confirmed leader for much of the past two years.

None of those decisions pauses while the Senate waits.

A pattern of pulled nominees

Overton is not the first health nominee the White House has pulled. The CDC nominee David Weldon was withdrawn, and two surgeon general nominees, including Casey Means, were pulled before confirmation.

A pattern is now visible. The administration has been willing to nominate people who satisfy one part of its coalition and then withdraw them when another part objects. That is a coalition-management strategy, and it has a cost: the agencies run on acting leadership for longer, and the next nominee inherits a shorter runway and a more skeptical Senate.

The pattern also weakens the committees. A senator who spends months preparing for a confirmation vote learns that the vote may be canceled before it happens. The incentive to invest in the process declines.

What the vacancy changes

The FDA will keep making decisions. The question is who owns them.

For drug and device companies, the practical difference is timing and predictability. A confirmed commissioner can set a direction and defend it in public. An acting commissioner can do the same, but with less authority and a shorter horizon, and the industry reads that difference in every guidance document and every approval letter.

For patients and clinicians, the difference is accountability. A confirmed commissioner is the person the Senate can summon, question and hold responsible. An acting commissioner is a temporary official in a permanent job, and the public has no confirmation record to read.

For the next Senate, the difference is leverage. If the confirmation falls to January, the Democrats will be negotiating from a different position, and the administration will be asking for a vote it could have had in November.

The Overton withdrawal is a loss for the nominee. It is also a decision about how the FDA will be run for the next several months. The agency's agenda did not shrink on Tuesday, and the person accountable for it is now an acting official.

Primary sources

  1. NBC News for the withdrawal and the White House's confirmation.
  2. The Guardian for the nomination timeline and the Senate vote.
  3. CNBC for the administration's explanation and the vote count.
  4. The New York Times for the HELP Committee schedule and the withdrawal.
  5. Politico for the Senate Republicans' concerns.
  6. CNN for the MAHA reaction and the Kennedy relationship.
  7. The New York Post for Cassidy's statement and the Axios report.